Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

PROximal Protection VErsus NON-Protection in Carotid Artery Stenting (PROVENON)

2. december 2011 opdateret af: Universität des Saarlandes

PROximal Protection VErsus NON-Protection in Carotid Artery Stenting (PROVENON Study) A Randomized Prospective MRI-based Trial.

To compare the incidence of new ischemic brain injury detected with magnetic resonance imaging (MRI) after carotid artery stenting in patients treated with and without proximal cerebral protection (Gore Flow Reversal System).

Studieoversigt

Detaljeret beskrivelse

Primary Objective:

The purpose of this study is to compare the rate of new ischemic brain injury detectable on MRI after carotid artery stenting between patients treated with proximal cerebral protection (Gore Flow Reversal System) and without cerebral protection.

Secondary Objective:

Impact of MRI-morphology of atherosclerotic plaque to the rate of new hyperintense diffusion weighted imaging (DWI) lesion on the post-treatment scan and to the rate of ipsilateral stroke or death.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

220

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Saarland
      • Homburg, Saarland, Tyskland, 66424
        • Rekruttering
        • Department of Diagnostic and Interventional Neuroradiology
        • Underforsker:
          • Christian Roth, MD
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Wolfgang Reith, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male and female ≥ 18 years old;
  • Suitable/Eligible for carotid artery revascularization;
  • Significant artery stenosis in symptomatic patients defined as ≥ 50% of the artery diameter (%DS) or asymptomatic ≥ 80 %DS by angiography. Symptomatic is defined as a carotid artery stenosis associated with ipsilateral transient ischemic attack (TIA), amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment.
  • Adequate clinical conditions to perform DW-MRI.
  • Ability of the individual to understand the character and the consequences of clinical trial.
  • Signed and dated informed consent provided before the beginning of any intervention.
  • Negative pregnancy test (serum or urine) and contraception use for any woman of childbearing age. Systematic contraceptives (oral, implant, injection) and dia-phragm or condoms with spermicidal are considered reliable. Women who have undergone bilateral oophorectomy or/and hysterectomy or women status post-menopausal for at least two years are eligible for this trial.

Exclusion Criteria:

  • Intracranial hemorrhage, hemorrhagic stroke, or stroke with mass effect demonstrated on CT scan or MRI within 30 days of the index procedure.
  • Persisting ischemic stroke (defined as either a score > 15 on the NIH stroke scale, a Rankin score > 3 or a Barthel score < 60 measured within one week prior to study entry).
  • Intracranial mass lesion (i.e., abscess, tumor, or other infection).
  • peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding the use of catheter-based techniques required for successful results.
  • Lactation.
  • Arterio-venous malformation in the territory of the target carotid artery.
  • Any disease or medication that affects local hemostasis,
  • Participation in other clinical trials during the present clinical trial or within the last month.
  • Medical or psychological condition that would not permit completion of the trial or signing of informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Carotid Artery Stenting without Protection
Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
Carotid artery angioplasty and stenting without cerebral embolic protection
Aktiv komparator: Carotid Artery Stenting with Proximal Protection
Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging
Tidsramme: Day 1-3
Day 1-3

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ipsilateral stroke (ischaemic stroke, intracerebral bleeding or both, with symptoms lasting more than 24 h) or death between treatment and 30 days after treatment
Tidsramme: Day 30
Day 30
Technical Success of the procedure
Tidsramme: Day 0

Subjects (both groups) who due to technical reaseons are unable to performe carotid artery stenting will be considered as technical failures.

Subjects who are unable to tolerate flow reversal (in group 2) and have their procedures completed without embolic protection or other methods will be also considered as technical failures.

Day 0
Access site vascular complications, defined as need for surgical repair or blood transfusion
Tidsramme: Day 0-7
Day 0-7

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Wolfgang Reith, MD, Saarland University Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2011

Primær færdiggørelse (Forventet)

1. maj 2014

Studieafslutning (Forventet)

1. juni 2014

Datoer for studieregistrering

Først indsendt

30. marts 2011

Først indsendt, der opfyldte QC-kriterier

6. april 2011

Først opslået (Skøn)

8. april 2011

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

5. december 2011

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. december 2011

Sidst verificeret

1. marts 2011

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Halspulsåren stenose

Kliniske forsøg med Carotid Artery Stenting without Protection

Abonner